David R. Bauer

Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…

Davis Polk advised the representatives of the underwriters in connection with the $122.4 million public offering of 4,800,000 shares of common stock by Flexion Therapeutics, Inc. The…

Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total…

Davis Polk advised Kadmon Holdings, Inc. in connection with an $80.4 million offering of 22,275,000 shares of common stock and warrants to purchase 8,910,000 shares of common stock, which…

 Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $750 million aggregate principal amount of its 3.000% senior…

Davis Polk advised the underwriter in connection with the $39.3 million SEC-registered offering of 2,500,000 ordinary shares of Oxford Immunotec Global PLC. The ordinary shares are…

Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5,296,053 shares of common stock of Spark Therapeutics, Inc. The…

Davis Polk advised Calyxt, Inc. in connection with its initial public offering of 8,050,000 shares of its common stock, including 1,050,000 shares of common stock sold pursuant to the full…

Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…

Davis Polk advised the joint book-running managers in connection with the $86.3 million initial public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on…